DocGo vs U S Physical Therapy
DCGO and USPH side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DCGO and USPH compare
U S Physical Therapy is the larger company, worth 66 times as much as DocGo ($1.5B against $22.3M).
U S Physical Therapy grew revenue faster over the last twelve months (10.4% versus −19.2% for DocGo).
U S Physical Therapy keeps more of each dollar of sales as profit, with a net margin of 3.6% compared with −61.0% at DocGo.
U S Physical Therapy pays a dividend yielding 1.9%; DocGo does not pay one.
U S Physical Therapy scores higher on the StockData Score (8 against 6 for DocGo), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DCGO | USPH |
|---|---|---|
| Size and price | ||
| Market cap | $22.3M | $1.5B |
| Share price | $0.225 | $98.60 |
| Change, 1 year | −79.5% | 32.5% |
| Change, 5 years | −97.6% | 8.3% |
| Beta (5Y) | 1.25 | 0.71 |
| Employees | 3,600 | 7,294 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 1 (better) |
| Valuation | ||
| P/S | 0.1× (better) | 1.8× |
| P/B | 0.2× (better) | 3.4× |
| EV/EBITDA | – | 17.1× |
| P/FCF | – | 21.3× |
| FCF yield | −136% | 4.7% (better) |
| Fair value | $2.17 | $80.31 |
| Margin of safety | 89.7% (better) | −22.8% |
| Growth | ||
| Revenue growth (TTM) | −19.2% | 10.4% (better) |
| Revenue growth, 5Y average | 27.9% (better) | 13.0% |
| Net income growth (TTM) | – | −32.5% |
| EPS growth, 5Y average | – | −10.6% |
| Profitability | ||
| Gross margin | – | 18.8% |
| Operating margin | −53.3% | 9.1% (better) |
| Net margin | −61.0% | 3.6% (better) |
| FCF margin | −10.2% | 8.2% (better) |
| Return on equity | −96.5% | 6.5% (better) |
| Return on invested capital | −88.3% | 9.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.57 |
| Net debt / EBITDA | – | 2.11 |
| Current ratio | 1.38 | 1.42 (better) |
| Altman Z-score | −2.81 | 2.83 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.9% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 41.3% |
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 1.9% (better) |
| Ownership | ||
| Held by institutions | 38.5% | 109% |
| Held by insiders | 9.8% | 2.6% |
| Insider net buying, 12 months | −$15.3K (better) | −$397K |
| Short interest, % of float | 2.4% | 7.8% |
Go deeper
- DCGO stock overview
- DCGO income statement
- DCGO valuation and score
- USPH stock overview
- USPH income statement
- USPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.